天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (6): 1261-1271.doi: 10.16333/j.1001-6880.2026.6.012 cstr: 32307.14.1001-6880.2026.6.012

• 开发研究 • 上一篇    下一篇

基于代谢组学的天山花楸水提物抗哮喘机制研究

王文凯1,李改茹1,马晓丽1,常军民1,2*   

  1. 1新疆医科大学药学院,乌鲁木齐 830011;2新疆天然药物活性组分与释药技术重点实验室,乌鲁木齐 830000
  • 出版日期:2026-06-26 发布日期:2026-06-24
  • 基金资助:
    新疆维吾尔自治区重大科技专项(2022A03007-3)

Antiasthmatic mechanism of water extract from Sorbus tianshanica Rupr. based on metabolomics

WANG Wen-kai1,LI Gai-ru1,MA Xiao-li1,CHANG Jun-min1,2*   

  1. 1College of Pharmacy,Xinjiang Medical University,Urumqi 830011,China;2Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology,Urumqi 830000,China
  • Online:2026-06-26 Published:2026-06-24

摘要:

研究天山花楸水提物(water extract of Sorbus tianshanica Rupr.STE对过敏性哮喘小鼠气道炎症的影响及其可能的作用机制。通过卵清蛋白诱导构建哮喘小鼠模型,将小鼠随机分为对照组、模型组、阳性药地塞米松组(2 mg/kg)、STE低剂量组(1 g/kg)、STE中剂量组(2 g/kg)及STE高剂量组(4 g/kg)。各组小鼠接受相应处理,连续灌胃治疗两周后通过ELISART-qPCRWestern blot检测相关炎症因子的表达水平,同时结合非靶向代谢组学分析与AutoDock软件分子对接,探索STE的潜在作用靶点及其抗哮喘机制。ELISA结果显示,与对照组相比,模型组小鼠血清免疫球蛋白Eimmunoglobulin EIgE和支气管肺泡灌洗液中白细胞介素-17Ainterleukin-17AIL-17A显著升高(P < 0.01),IL-10显著降低(P < 0.01);STE高剂量组显著降低IgEIL-17AP < 0.01),同时增加IL-10水平(P < 0.01)。RT-qPCRWestern blot结果表明,与模型组小鼠相比,STE高剂量组显著上调肺组织中叉头状转录因子P3(forkhead box protein P3,FOXP3)表达(P < 0.01),下调维甲酸相关孤儿受体γt(retinoid acid-related orphan receptor γt,RORγt)表达(P < 0.01)。而代谢组学及分子对接分析进一步揭示,STE可能通过调控脂肪酸和氨基酸代谢通路,抑制促炎信号、增强抗炎机制发挥作用。综上所述,STE通过上调抗炎因子IL-10FOXP3的表达,同时抑制促炎因子IL-17ARORγt的活性,调节辅助性T细胞17(T helper 17 cells,Th17)/调节性T细胞(regulatory T cell,Treg)细胞平衡及相关代谢通路,从而改善哮喘小鼠气道炎症。

关键词: 非靶向代谢组学, 天山花楸水提物, 哮喘, 叉头状转录因子P3, 维甲酸相关孤儿受体γt

Abstract:

This study aims to investigate the effects of the water extract of Sorbus tianshanica Rupr. (STE) on airway inflammation in a murine model of allergic asthma and its potential underlying mechanisms. An asthma mouse model was established by ovalbumin induction. The mice were randomly assigned to six groups: control group, model group, positive control group treated with dexamethasone (2 mg/kg), low-dose STE group (1 g/kg), medium-dose STE group (2 g/kg), and high-dose STE group (4 g/kg). Mice in each group received the corresponding treatment, and after two weeks of continuous oral gavage, the expression levels of relevant inflammatory factors were assessed using ELISA, RT-qPCR and Western blot methods. In addition, untargeted metabolomic analysis combined with molecular docking using AutoDock software was performed to explore the potential targets and anti-asthmatic mechanisms of STE. ELISA results showed that, compared with control group, immunoglobulin E (IgE) in serum and interleukin-17A (IL-17A) levels in bronchoalveolar lavage fluid were markedly higher (P < 0.01), while IL-10 levels were significantly lower (P < 0.01) in model mice. High-dose STE treatment markedly suppressed IgE and IL-17A (P < 0.01) and boosted IL-10 levels (P < 0.01). RT-qPCR and Western blot results showed that, compared with the model group, the high-dose STE group significantly upregulated the expression of forkhead box protein P3 (FOXP3) (P < 0.01) and downregulated the expression of retinoid acid-related orphan receptor γt (RORγt) (P < 0.01) in lung tissues. Metabolomic and molecular docking analyses further revealed that STE may exert its effects by regulating fatty acid and amino acid metabolism pathways, inhibiting pro-inflammatory signaling, and enhancing anti-inflammatory mechanisms. In summary, STE improves airway inflammation by modulating the balance between T helper 17 (Th17) and regulatory T cells (Treg), upregulating the expression of anti-inflammatory factors IL-10 and FOXP3, and downregulating the activity of pro-inflammatory factors IL-17A and RORγt.

Key words: untargeted metabolomics, Sorbus tianschanica Rupr., asthma, FOXP3, RORγt

中图分类号:  R96